Retrotope Announces Completion of Enrollment in Phase II Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Retrotope announced that enrollment has been completed for its multicenter Phase II clinical trial evaluating RT001, the company’s lead development candidate, in patients with ALS or Lou Gehrig’s disease.